DETECTION WITHOUT DIRECTION: THE CLINICAL SIGNIFICANCE OF SUBCLINICAL ATRIAL FIBRILLATION IN STROKE PREVENTION

Abstract

The increasing use of long-term cardiac monitoring in patients with cryptogenic stroke has led to a marked rise in the detection of arrhythmias, particularly subclinical atrial fibrillation (AF). While this improved detection represents a clear step forward, it also introduces new clinical uncertainty.

AF has traditionally been viewed as a direct cause of thromboembolic stroke. However, emerging evidence suggests that this relationship is more complex, especially in the context of short, device-detected episodes. Major trials, including ASSERT, CRYSTAL-AF, LOOP, ARTESiA, and NOAH-AFNET 6, consistently show that although subclinical AF is associated with increased stroke risk, its detection alone does not reliably translate into improved outcomes when used as a trigger for anticoagulation under current guideline frameworks.

This uncertainty is further reinforced by the lack of clear temporal association between AF episodes and stroke, as well as the absence of validated burden thresholds defining clinically meaningful arrhythmia.

Concepts such as atrial cardiopathy suggest that AF may act more as a marker of an underlying prothrombotic substrate than as a direct causal mechanism. This perspective shifts the focus away from AF as a binary finding toward a model in which stroke risk emerges from the interaction between arrhythmic burden, clinical risk profile, and structural atrial disease.

Taken together, these findings highlight the limitations of current AF-centered approaches and support the need for a more integrated and clinically nuanced strategy for risk stratification and treatment decisions.